Total Payments
$1.4M
2024 Payments
$134,678
Companies
75
Transactions
1,834
Medicare Patients
17,330
Medicare Billing
$3.5M
Payment Breakdown by Category
Other$1.2M (91.1%)
Food & Beverage$44,255 (3.3%)
Travel$41,608 (3.1%)
Consulting$34,775 (2.6%)
Education$472.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 485 | 89.4% |
| Food and Beverage | $44,255 | 1,231 | 3.3% |
| Travel and Lodging | $41,608 | 81 | 3.1% |
| Consulting Fee | $34,775 | 13 | 2.6% |
| Long term medical supply or device loan | $11,458 | 2 | 0.8% |
| Honoraria | $7,200 | 3 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,000 | 3 | 0.3% |
| Education | $472.00 | 16 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $323,150 | 283 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $312,644 | 275 | $0 (2024) |
| Novo Nordisk Inc | $172,228 | 98 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $161,566 | 208 | $0 (2024) |
| Lilly USA, LLC | $136,079 | 126 | $0 (2024) |
| Medtronic, Inc. | $59,535 | 72 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $38,417 | 31 | $0 (2024) |
| Relypsa, Inc. | $33,845 | 45 | $0 (2019) |
| Medtronic Vascular, Inc. | $29,059 | 51 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $14,482 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $134,678 | 209 | Bayer Healthcare Pharmaceuticals Inc. ($36,699) |
| 2023 | $112,672 | 226 | Novo Nordisk Inc ($37,497) |
| 2022 | $185,512 | 262 | Novo Nordisk Inc ($84,499) |
| 2021 | $126,746 | 184 | Boehringer Ingelheim Pharmaceuticals, Inc. ($38,713) |
| 2020 | $85,208 | 152 | Lilly USA, LLC ($32,081) |
| 2019 | $212,959 | 256 | Janssen Pharmaceuticals, Inc ($86,554) |
| 2018 | $250,026 | 281 | Boehringer Ingelheim Pharmaceuticals, Inc. ($78,858) |
| 2017 | $249,791 | 264 | Novartis Pharmaceuticals Corporation ($94,800) |
All Payment Transactions
1,834 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | AngioDynamics, Inc. | Auryon Laser System 100-120 Vac (Device) | Long term medical supply or device loan | In-kind items and services | $7,500.00 | General |
| Category: ET | ||||||
| 12/30/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/20/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Obesity | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.32 | General |
| 12/17/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/17/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/12/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $10.60 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $102.46 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/10/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: EndoVenous Therapies | ||||||
| 12/09/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $99.09 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/02/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/27/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $95.76 | General |
| Category: Cardiology | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.23 | General |
| 11/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Cardio-renal | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 4,859 | 12,561 | $3.1M | $868,061 |
| 2022 | 55 | 4,219 | 10,085 | $3.2M | $914,702 |
| 2021 | 51 | 3,740 | 10,167 | $2.9M | $872,788 |
| 2020 | 50 | 4,512 | 10,541 | $2.8M | $853,886 |
Total Patients
17,330
Total Services
43,354
Medicare Billing
$3.5M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 2 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 37253 | Ultrasound evaluation of blood vessel with review by radiologist, each additional vessel | Office | 2023 | 22 | 34 | $18,226 | $4,757 | 26.1% |
| 93454 | Insertion of tube in coronary artery for diagnosis with review by radiologist | Facility | 2023 | 26 | 26 | $13,250 | $4,619 | 34.9% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 20 | 20 | $12,470 | $4,414 | 35.4% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 24 | 85 | $13,345 | $4,197 | 31.5% |
| 99091 | Collection and interpretation of physical parameters stored in computers and/or transmitted by the patient and/or caregiver to qualified health care professional, requiring 30 minutes or more, per 30 days | Office | 2023 | 62 | 92 | $12,880 | $4,036 | 31.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 174 | 178 | $12,190 | $3,739 | 30.7% |
| 75716 | Review by radiologist of both arms or legs arteries image | Office | 2023 | 26 | 28 | $69,501 | $3,709 | 5.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 198 | 318 | $16,590 | $3,289 | 19.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 50 | $10,135 | $3,211 | 31.7% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 156 | 161 | $10,562 | $3,172 | 30.0% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 28 | 36 | $10,900 | $3,032 | 27.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $6,640 | $2,111 | 31.8% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Office | 2023 | 34 | 41 | $6,334 | $1,653 | 26.1% |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | Office | 2023 | 34 | 4,503 | $8,691 | $1,498 | 17.2% |
| 93463 | Drug infusion during cardiac catheterization | Facility | 2023 | 16 | 17 | $3,455 | $1,346 | 39.0% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 69 | 72 | $3,528 | $1,109 | 31.4% |
| 99153 | Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | Office | 2023 | 34 | 109 | $3,803 | $987.18 | 26.0% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 13 | 14 | $2,482 | $649.36 | 26.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 13 | 13 | $2,353 | $640.12 | 27.2% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 14 | 15 | $1,830 | $572.10 | 31.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 12 | $1,764 | $335.70 | 19.0% |
| 80047 | Blood test, basic group of blood chemicals (calcium, ionized) | Office | 2023 | 21 | 24 | $984.00 | $323.04 | 32.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 34 | 37 | $706.00 | $292.07 | 41.4% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 22 | 23 | $2,387 | $242.19 | 10.1% |
| J0280 | Injection, aminophyllin, up to 250 mg | Office | 2023 | 12 | 12 | $240.00 | $83.86 | 34.9% |
About Tamam Mohamad
Tamam Mohamad is a Cardiovascular Disease healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2009. The National Provider Identifier (NPI) number assigned to this provider is 1457687584.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Tamam Mohamad has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $134,678 received in 2024. These payments were reported across 1,834 transactions from 75 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Mohamad has provided services to 17,330 Medicare beneficiaries, totaling 43,354 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties General Acute Care Hospital, Interventional Cardiology
- Location Detroit, MI
- Active Since 10/24/2009
- Last Updated 04/23/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1457687584
Products in Payments
- JARDIANCE (Drug) $439,728
- XARELTO (Drug) $312,644
- ENTRESTO (Drug) $160,934
- Ozempic (Drug) $113,513
- VENASEAL (Device) $39,830
- Kerendia (Drug) $38,417
- Veltassa (Drug) $33,845
- ClosureFast (Device) $28,611
- VenaSeal (Device) $19,541
- Rybelsus (Drug) $14,525
- BRILINTA (Drug) $14,225
- TRULICITY (Drug) $13,833
- Auryon Laser System 100-120 Vac (Device) $11,458
- LifeVest (Device) $10,308
- Impella (Device) $7,766
- RYBELSUS (Drug) $7,013
- PRALUENT (Drug) $5,048
- FLEXITOUCH PLUS (Device) $4,746
- PRALUENT ALIROCUMAB INJECTION (Biological) $4,636
- Peripheral Orbital Atherectomy System (Device) $4,459
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Detroit
Wayne Douglas Weaver, M.d, M.D
Cardiovascular Disease — Payments: $360,582
Cardiovascular Disease $360,582
Dr. Brian O'neill, M.d, M.D
Cardiovascular Disease — Payments: $182,193
Cardiovascular Disease $182,193
Dr. Brian Ference, Md, MD
Cardiovascular Disease — Payments: $160,503
Cardiovascular Disease $160,503
David Lanfear, M.d, M.D
Cardiovascular Disease — Payments: $160,449
Cardiovascular Disease $160,449
Dr. Mahir Elder, Md, MD
Cardiovascular Disease — Payments: $132,144
Cardiovascular Disease $132,144
Dr. Zaher Hakim, M.d, M.D
Cardiovascular Disease — Payments: $93,632
Cardiovascular Disease $93,632